Table 2. HIV-1 assay results from PrEP Participant B longitudinal blood and tissue sampling.
| Lab/ Location | Days Post-ART | Sample Type | Assay Type | Result | Sample Volume Tested or LOD |
|---|---|---|---|---|---|
| UCSF | 91 | PBMC (leukapheresis) | HIV RNA/DNA | 14.3 DNA c/106 CD4+ TEM; 2.9 RNA c/106 CD4+ TTM | 1 to 5.7 (RNA) and 14 to 14.2 (DNA) copies/106 cells |
| UCSF | 266 | PBMC | HIV RNA/DNA | 2.4 RNA c/106 total CD4+ T cells; DNA Neg | 12.4 DNA copies/106 cells |
| UCSF | 271 | PBMC1 (leukapheresis) | HIV RNA/DNA | 5.5 RNA c/106 CD4+ T cells; DNA and RNA neg from immune subsets | 1.6 to 7.6 (RNA) and 11.6 to 664 (DNA) copies/106cells |
| UCSF | 272 | Lymph Node1 (inguinal, sorted) | HIV RNA/DNA | Neg | 13.7 to 18302 (DNA) and 1.3 to 3.9 copies/106cells |
| UCSF | 279 | Bone Marrow (sorted)2 |
HIV RNA/DNA | Neg | 0.2 to 15.8 (RNA) and 10.5 to 83 (DNA) copies/106 cells |
| UCSF | 656 | PBMC | HIV RNA/DNA | Neg | 6.3 (RNA) and 21.9 (DNA) copies/106 cells |
| Hopkins (Blankson) | 523 | PBMC (leukapheresis) |
mVOA | 3/8 mice viremic (1,000, 5,000, 11,000 c/mL plasma) | 500 million CD4+ T cells |
| Hopkins (Siliciano) | 761 | PBMC (leukapheresis) | Whole Genome Sequencing | Neg | 15 million resting CD4+ T cells |
| UCSF | 966 | PBMC (leukapheresis) | qVOA | Neg | 30 million total CD4+ T cells |
1 DNA and RNA obtained from sorted CD4+ T cell immune subsets (TN, TCM, TEM, and TTM).
2 DNA and RNA obtained from sorted CD4+ T cells, common lymphoid progenitor cells, hematopoietic stem/progenitor cells, and myeloid cells.
Abbreviations: ART, antiretroviral therapy; c/mL, copies/mL; GALT, gut-associated lymphoid tissue; LOD, limit of detection; Neg, negative; PBMC, peripheral blood mononuclear cells; PrEP, pre-exposure prophylaxis; qVOA, qVOA, quantitative viral outgrowth assay; UCSF, University of California San Francisco.